Dedicated to transforming the care of people living with rare genetic diseases of obesity
Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)
Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)
Solomon and Adalissa, siblings living with Bardet-Biedl syndrome
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating hunger and energy expenditure, and consequently, body weight.
An impaired MC4R pathway may lead to rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and a pathological insatiable hunger or hyperphagia.
We are targeting the MC4R pathway to develop therapeutics for rare genetic diseases of obesity with an integrated precision medicine approach that combined our translational research and clinical development.
Learn about our translational research based on the largest known DNA database focused on obesity.
Learn about our clinical development programs with trials in patients with rare obesities linked to variants in certain genes with strong or very strong relevance to the MC4R pathway.
Dedicated to transforming the care of people living with rare genetic diseases of obesity
Mike and Tysen, father and son living with POMC insufficiency obesity (heterozygous)
Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)
Solomon and Adalissa, siblings living with Bardet-Biedl syndrome
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
Joan, wife to Mike and mother to Tysen, both diagnosed with POMC insufficiency obesity (heterozygous)
Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome
We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.
By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic diseases of obesity, including:
Proopiomelanocortin
|
Leptin Receptor (LEPR)
|
Bardet-Biedl
|
Alström
|
POMC or LEPR
|
Smith-Magenis
|
SRC1 Deficiency
|
MC4R Deficiency
|
SH2B1 Deficiency
|
